Background & Aims Oral antiviral therapy with nucleos (t) ide analogues (NAs) for chronic
hepatitis B (CHB) is well-tolerated and lifesaving, but real-world data on utilization are …

Background & Aims It is unclear if there may be sex differences in response to nucleos (t) ide
analogs including virologic response (VR), biochemical response (BR), complete response …

Nucleos (t) ide analogues (NAs) are widely used for antiviral therapy in patients with chronic
hepatitis B (CHB), but real-world data on treatment patterns and long-term clinical outcomes …

Background Long-term monotherapy with nucleos (t) ide analogs (NAs) represents the
treatment option for the majority of patients with chronic hepatitis B (CHB), an aging …

Widespread and long‐term use of oral nucleos (t) ide analogs (NAs) to treat chronic hepatitis
B (CHB) brings about safety data in a real‐life setting. We aimed to determine the risks of …

Background & Aims Chronic hepatitis B (CHB) disproportionately impacts foreign-born
patients and those of Asian or Black race. Given the paucity of data, we aimed to study the …

Abstract Background and Objectives Previous studies have found that a major proportion of
patients with chronic hepatitis B (CHB) do not receive antiviral therapy. The objective of this …

Abstract Background and Aims: Chronic hepatitis B virus (HBV) infection remains a major
public health problem globally. Here, we describe the baseline characteristics and treatment …

Successful treatment outcomes for chronic hepatitis B virus (HBV) infection requires high
levels of adherence to treatment. We searched three databases and abstracts from two …

Background: Nucleos (t) ide analog (NA) in combination with peginterferon (PegIFN) therapy
in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) shows …